Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 25;11(11):729.
doi: 10.3390/metabo11110729.

Single-Cell Multiomics Analysis for Drug Discovery

Sam F Nassar  1   2 , Khadir Raddassi  3 , Terence Wu  4
Affiliations
Review

Single-Cell Multiomics Analysis for Drug Discovery

Sam F Nassar et al. Metabolites. .

Abstract

Given the heterogeneity seen in cell populations within biological systems, analysis of single cells is necessary for studying mechanisms that cannot be identified on a bulk population level. There are significant variations in the biological and physiological function of cell populations due to the functional differences within, as well as between, single species as a result of the specific proteome, transcriptome, and metabolome that are unique to each individual cell. Single-cell analysis proves crucial in providing a comprehensive understanding of the biological and physiological properties underlying human health and disease. Omics technologies can help to examine proteins (proteomics), RNA molecules (transcriptomics), and the chemical processes involving metabolites (metabolomics) in cells, in addition to genomes. In this review, we discuss the value of multiomics in drug discovery and the importance of single-cell multiomics measurements. We will provide examples of the benefits of applying single-cell omics technologies in drug discovery and development. Moreover, we intend to show how multiomics offers the opportunity to understand the detailed events which produce or prevent disease, and ways in which the separate omics disciplines complement each other to build a broader, deeper knowledge base.

Keywords: COVID-19; IsoLight; genomics; mass spectrometry; metabolomics; multiomics; proteomics; single-cell; transcriptomics.

PubMed Disclaimer

Conflict of interest statement

Sam F. Nassar had no role in the design, execution, interpretation, or writing of the study.

References

    1. Nassar A.-E.F., Kamel A.M., Clarimont C. Improving the Decision-Making Process in Structural Modification of Drug Candidates: Reduce Toxicity. Drug Discov. Today. 2004;9:1055–1064. doi: 10.1016/S1359-6446(04)03297-0. - DOI - PubMed
    1. Nassar A.-E.F., Kamel A.M., Clarimont C. Improving the Decision-Making Process in the Structural Modification of Drug Candidates: Enhance Metabolic Stability. Drug Discov. Today. 2004;9:1020–1028. doi: 10.1016/S1359-6446(04)03280-5. - DOI - PubMed
    1. Bolognesi M.L., Cavalli A. Multitarget Drug Discovery and Polypharmacology. ChemMedChem. 2016;11:1190–1192. doi: 10.1002/cmdc.201600161. - DOI - PubMed
    1. Safety Pharmacology Studies for Human Pharmaceuticals S7A. [(accessed on 5 October 2021)]. Available online: http://www.ich.org/LOB/media/MEDIA504.pdf.
    1. Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use S2(R1) [(accessed on 5 October 2021)]. Available online: http://www.ich.org/LOB/media/MEDIA4474.pdf.

LinkOut - more resources